SNGX
Soligenix, Inc.
Biotechnology
Market Cap$3M
5Y Perf.-99.9%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
SNGX vs XTLB vs ADXN vs NUVB vs HALO
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$294K
5Y Perf.-60.7%
ADXN
Addex Therapeutics Ltd
Biotechnology
Market Cap$5M
5Y Perf.-97.7%
NUVB
Nuvation Bio Inc.
Biotechnology
Market Cap$1.67B
5Y Perf.-51.8%
HALO
Halozyme Therapeutics, Inc.
Biotechnology
Market Cap$7.68B
5Y Perf.+124.8%
SNGX vs XTLB vs ADXN vs NUVB vs HALO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SNGX | XTLB | ADXN | NUVB | HALO |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $3M | $294K | $5M | $1.67B | $7.68B |
| Revenue (TTM) | $0.00 | $451K | $68K | $143M | $1.40B |
| Net Income (TTM) | $-11M | $-1M | $-6M | $-146M | $317M |
| Gross Margin | — | 26.4% | -246.8% | 91.6% | 81.9% |
| Operating Margin | — | -481.6% | -36.7% | -105.0% | 58.4% |
| Forward P/E | — | — | 0.7x | — | 8.1x |
| Total Debt | $1M | $138K | $42K | $10M | $0.00 |
| Cash & Equiv. | $8M | $371K | $3M | $164M | $134M |
SNGX vs XTLB vs ADXN vs NUVB vs HALO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SNGX
XTLB
ADXN
NUVB
HALO
| Stock | Aug 20 | May 26 | Return |
|---|---|---|---|
| Soligenix, Inc. (SNGX) | 100 | 0.1 | -99.9% |
| XTL Biopharmaceutic… (XTLB) | 100 | 39.3 | -60.7% |
| Addex Therapeutics … (ADXN) | 100 | 2.3 | -97.7% |
| Nuvation Bio Inc. (NUVB) | 100 | 48.2 | -51.8% |
| Halozyme Therapeuti… (HALO) | 100 | 224.8 | +124.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SNGX vs XTLB vs ADXN vs NUVB vs HALO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HALO leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Nuvation Bio Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. ADXN also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
SNGX
Soligenix, Inc.
The Healthcare Pick
SNGX lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
XTLB
XTL Biopharmaceuticals Ltd.
The Healthcare Pick
Among these 5 stocks, XTLB doesn't own a clear edge in any measured category.
Best for: healthcare exposure
ADXN
Addex Therapeutics Ltd
The Defensive Pick
ADXN ranks third and is worth considering specifically for sleep-well-at-night.
- Lower volatility, beta 0.59, Low D/E 0.4%, current ratio 4.42x
- Lower P/E (0.7x vs 8.1x)
Best for: sleep-well-at-night
NUVB
Nuvation Bio Inc.
The Growth Play
NUVB is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 7.0%, EPS growth 71.6%
- 7.0% revenue growth vs XTLB's -173.2%
- +136.3% vs SNGX's -84.4%
Best for: growth exposure
HALO
Halozyme Therapeutics, Inc.
The Income Pick
HALO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.56
- 5.7% 10Y total return vs NUVB's -51.8%
- Beta 0.56, current ratio 4.66x
- 22.7% margin vs ADXN's -90.2%
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NUVB | 7.0% revenue growth vs XTLB's -173.2% |
| Value | ADXN | Lower P/E (0.7x vs 8.1x) |
| Quality / Margins | HALO | 22.7% margin vs ADXN's -90.2% |
| Stability / Safety | HALO | Beta 0.56 vs NUVB's 2.04 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | NUVB | +136.3% vs SNGX's -84.4% |
| Efficiency (ROA) | HALO | 12.5% ROA vs SNGX's -135.7% |
SNGX vs XTLB vs ADXN vs NUVB vs HALO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
FY 2024
FY 2025
FY 2025
SNGX vs XTLB vs ADXN vs NUVB vs HALO — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHALOLAGGINGADXN
Who Leads Where
HALO leads in 2 of 6 categories
XTLB leads 1 • NUVB leads 1 • SNGX leads 0 • ADXN leads 0 • 1 tied
Explore the data ↓ADXNAddex Therapeutics Ltd
0leads
SNGXSoligenix, Inc.
0leads
NUVBNuvation Bio Inc.
1leads
XTLBXTL Biopharmaceutical…
1leads
HALOHalozyme Therapeutics…
2leads
6 Total Categories
CATEGORYLEADERvs XTLBvs NUVBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
XTLB2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HALO7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NUVB3/6
Risk & VolatilityBeta, volatility, and downside exposure
HALO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — NUVB and HALO each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HALO and SNGX operate at a comparable scale, with $1.4B and $0 in trailing revenue. HALO is the more profitable business, keeping 22.7% of every revenue dollar as net income compared to ADXN's -90.2%. On growth, NUVB holds the edge at +26.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SNGXSoligenix, Inc. | XTLBXTL Biopharmaceut… | ADXNAddex Therapeutic… | NUVBNuvation Bio Inc. | HALOHalozyme Therapeu… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $451,000 | $67,607 | $143M | $1.4B |
| EBITDAEarnings before interest/tax | -$12M | -$1M | -$2M | -$145M | $945M |
| Net IncomeAfter-tax profit | -$11M | -$1M | -$6M | -$146M | $317M |
| Free Cash FlowCash after capex | -$10M | $0 | -$2M | -$126M | $645M |
| Gross MarginGross profit ÷ Revenue | — | +26.4% | -2.5% | +91.6% | +81.9% |
| Operating MarginEBIT ÷ Revenue | — | -4.8% | -36.7% | -105.0% | +58.4% |
| Net MarginNet income ÷ Revenue | — | -2.3% | -90.2% | -102.1% | +22.7% |
| FCF MarginFCF ÷ Revenue | — | -3.7% | -23.3% | -88.1% | +46.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | -44.8% | +26.0% | +51.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +25.6% | +20.0% | +11.2% | +106.3% | -2.1% |
Evenly matched — NUVB and HALO each lead in 3 of 6 comparable metrics.
Valuation Metrics
XTLB leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
At 0.7x trailing earnings, ADXN trades at a 97% valuation discount to HALO's 25.5x P/E.
| Metric | SNGXSoligenix, Inc. | XTLBXTL Biopharmaceut… | ADXNAddex Therapeutic… | NUVBNuvation Bio Inc. | HALOHalozyme Therapeu… |
|---|---|---|---|---|---|
| Market CapShares × price | $3M | $293,767 | $5M | $1.7B | $7.7B |
| Enterprise ValueMkt cap + debt − cash | -$3M | $60,767 | $394,716 | $1.5B | $7.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.06x | -0.28x | 0.65x | -8.03x | 25.46x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | 8.09x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 1.11x |
| EV / EBITDAEnterprise value multiple | — | — | — | — | 8.34x |
| Price / SalesMarket cap ÷ Revenue | — | 0.65x | 8.93x | 26.61x | 5.50x |
| Price / BookPrice ÷ Book value/share | 0.12x | 0.05x | 0.46x | 5.38x | 165.47x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 11.91x |
XTLB leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
HALO leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
HALO delivers a 6.5% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-3 for SNGX. ADXN carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to SNGX's 0.36x. On the Piotroski fundamental quality scale (0–9), HALO scores 5/9 vs SNGX's 2/9, reflecting solid financial health.
| Metric | SNGXSoligenix, Inc. | XTLBXTL Biopharmaceut… | ADXNAddex Therapeutic… | NUVBNuvation Bio Inc. | HALOHalozyme Therapeu… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.7% | -25.5% | -78.3% | -44.1% | +6.5% |
| ROA (TTM)Return on assets | -135.7% | -17.7% | -67.7% | -23.8% | +12.5% |
| ROICReturn on invested capital | — | -54.1% | -103.3% | -54.3% | +73.4% |
| ROCEReturn on capital employed | -2.4% | -50.7% | -47.4% | -42.8% | +38.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 | 4 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.36x | 0.03x | 0.00x | 0.03x | — |
| Net DebtTotal debt minus cash | -$6M | -$233,000 | -$3M | -$154M | -$134M |
| Cash & Equiv.Liquid assets | $8M | $371,000 | $3M | $164M | $134M |
| Total DebtShort + long-term debt | $1M | $138,000 | $41,994 | $10M | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | -13.31x | -1857.72x | -162.11x | 46.08x |
HALO leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NUVB leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HALO five years ago would be worth $13,704 today (with dividends reinvested), compared to $10 for SNGX. Over the past 12 months, NUVB leads with a +136.3% total return vs SNGX's -84.4%. The 3-year compound annual growth rate (CAGR) favors NUVB at 43.8% vs SNGX's -73.5% — a key indicator of consistent wealth creation.
| Metric | SNGXSoligenix, Inc. | XTLBXTL Biopharmaceut… | ADXNAddex Therapeutic… | NUVBNuvation Bio Inc. | HALOHalozyme Therapeu… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -78.3% | +11.3% | -13.3% | -43.8% | -7.3% |
| 1-Year ReturnPast 12 months | -84.4% | -50.9% | -13.1% | +136.3% | -7.1% |
| 3-Year ReturnCumulative with dividends | -98.1% | -45.7% | -52.0% | +197.5% | +115.3% |
| 5-Year ReturnCumulative with dividends | -99.9% | -80.4% | -96.5% | -58.3% | +37.0% |
| 10-Year ReturnCumulative with dividends | -100.0% | -87.3% | -96.9% | -51.8% | +570.7% |
| CAGR (3Y)Annualised 3-year return | -73.5% | -18.4% | -21.7% | +43.8% | +29.1% |
NUVB leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
HALO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HALO is the less volatile stock with a 0.56 beta — it tends to amplify market swings less than NUVB's 2.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HALO currently trades 79.3% from its 52-week high vs SNGX's 4.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SNGXSoligenix, Inc. | XTLBXTL Biopharmaceut… | ADXNAddex Therapeutic… | NUVBNuvation Bio Inc. | HALOHalozyme Therapeu… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.97x | 1.71x | 0.59x | 2.04x | 0.56x |
| 52-Week HighHighest price in past year | $6.23 | $10.28 | $12.05 | $9.75 | $82.22 |
| 52-Week LowLowest price in past year | $0.30 | $1.05 | $5.41 | $1.57 | $47.50 |
| % of 52W HighCurrent price vs 52-week peak | +4.9% | +26.0% | +58.2% | +49.4% | +79.3% |
| RSI (14)Momentum oscillator 0–100 | 19.8 | 57.0 | 51.3 | 59.1 | 52.4 |
| Avg Volume (50D)Average daily shares traded | 722K | 2.4M | 4K | 4.3M | 1.4M |
HALO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NUVB as "Buy", HALO as "Buy". Consensus price targets imply 157.3% upside for NUVB (target: $12) vs 20.2% for HALO (target: $78).
| Metric | SNGXSoligenix, Inc. | XTLBXTL Biopharmaceut… | ADXNAddex Therapeutic… | NUVBNuvation Bio Inc. | HALOHalozyme Therapeu… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | — | $12.40 | $78.33 |
| # AnalystsCovering analysts | — | — | — | 9 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | +4.5% |
Insufficient data to determine a leader in this category.
Key Takeaway
HALO leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). XTLB leads in 1 (Valuation Metrics). 1 tied.
Best OverallHalozyme Therapeutics, Inc. (HALO)Leads 2 of 6 categories
Loading custom metrics...
SNGX vs XTLB vs ADXN vs NUVB vs HALO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SNGX or XTLB or ADXN or NUVB or HALO a better buy right now?
For growth investors, Nuvation Bio Inc.
(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -74. 9% for Addex Therapeutics Ltd (ADXN). Addex Therapeutics Ltd (ADXN) offers the better valuation at 0. 7x trailing P/E, making it the more compelling value choice. Analysts rate Nuvation Bio Inc. (NUVB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SNGX or XTLB or ADXN or NUVB or HALO?
On trailing P/E, Addex Therapeutics Ltd (ADXN) is the cheapest at 0.
7x versus Halozyme Therapeutics, Inc. at 25. 5x.
03Which is the better long-term investment — SNGX or XTLB or ADXN or NUVB or HALO?
Over the past 5 years, Halozyme Therapeutics, Inc.
(HALO) delivered a total return of +37. 0%, compared to -99. 9% for Soligenix, Inc. (SNGX). Over 10 years, the gap is even starker: HALO returned +570. 7% versus SNGX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SNGX or XTLB or ADXN or NUVB or HALO?
By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.
(HALO) is the lower-risk stock at 0. 56β versus Nuvation Bio Inc. 's 2. 04β — meaning NUVB is approximately 265% more volatile than HALO relative to the S&P 500. On balance sheet safety, Addex Therapeutics Ltd (ADXN) carries a lower debt/equity ratio of 0% versus 36% for Soligenix, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SNGX or XTLB or ADXN or NUVB or HALO?
By revenue growth (latest reported year), Nuvation Bio Inc.
(NUVB) is pulling ahead at 699. 0% versus -74. 9% for Addex Therapeutics Ltd (ADXN). On earnings-per-share growth, the picture is similar: Addex Therapeutics Ltd grew EPS 150. 0% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SNGX or XTLB or ADXN or NUVB or HALO?
Addex Therapeutics Ltd (ADXN) is the more profitable company, earning 1746% net margin versus -325.
3% for Nuvation Bio Inc. — meaning it keeps 1746% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -681. 8% for ADXN. At the gross margin level — before operating expenses — ADXN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SNGX or XTLB or ADXN or NUVB or HALO more undervalued right now?
Analyst consensus price targets imply the most upside for NUVB: 157.
3% to $12. 40.
08Which pays a better dividend — SNGX or XTLB or ADXN or NUVB or HALO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is SNGX or XTLB or ADXN or NUVB or HALO better for a retirement portfolio?
For long-horizon retirement investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Soligenix, Inc. (SNGX) carries a higher beta of 1. 97 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +570. 7%, SNGX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SNGX and XTLB and ADXN and NUVB and HALO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SNGX is a small-cap quality compounder stock; XTLB is a small-cap quality compounder stock; ADXN is a small-cap deep-value stock; NUVB is a small-cap high-growth stock; HALO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.